Financials
| Interim Results | Aug. 01, 2024 |
| Publication of 2023 Annual Report & Notice of AGM | Jun. 26, 2024 |
| Interim Results | Sep. 19, 2023 |
| BiVictriX Full Year Results | Mar. 30, 2023 |
| BiVictriX Interim Results | Sep. 12, 2022 |
| BiVictriX Full Year Results | Mar. 07, 2022 |
| Interim Results | Sep. 22, 2021 |
Proxies
| Result of Annual General Meeting | Jul. 24, 2024 |
| Result of Annual General Meeting | May. 04, 2023 |
| Publication of Annual Report and Notice of AGM | Mar. 31, 2023 |
| Result of AGM | Mar. 31, 2022 |
Ownership Update
| Holding(s) in Company | Sep. 10, 2024 |
| Holding(s) in Company | Sep. 02, 2024 |
| Director Dealing | Sep. 02, 2024 |
| Holding(s) in Company | Aug. 28, 2024 |
| TR-1: Notification of major holdings | Aug. 19, 2024 |
| Grant of Options | Aug. 13, 2024 |
| Holding(s) in Company | Jan. 04, 2024 |
Announcements
| Last Day of Dealings | Sep. 10, 2024 |
| Positive In Vivo Data from BVX002 Programme | Sep. 09, 2024 |
| Result of General Meeting | Aug. 29, 2024 |
| Proposed Voluntary Delisting | Aug. 12, 2024 |
| Compelling Safety Profile of BVX001 | Jun. 13, 2024 |
| Innovate UK Grant Award to Accelerate ADC Pipeline | Jun. 06, 2024 |
| Orphan Drug Designation & FDA INTERACT Meeting | Apr. 17, 2024 |